{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:37Z","timestamp":1787020237769,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination chemoimmunotherapy (CIT) consisting of anti-CD20 has improved the progression-free survival (PFS) and overall survival (OS) of patients with chronic lymphocytic leukaemia (CLL). We performed a comprehensive synthesis of prognostic factors in patients with CLL on combined CIT with anti-CD20 antibodies compared with standard chemotherapy alone or targeted therapy.<\/jats:p>\n                  <jats:p>We searched the MEDLINE and academic search complete electronic databases as well as clinicaltrials.gov (from inception up to 01 August 2022) for randomised controlled trials examining chemoimmunotherapy and targeted therapy in patients with CLL. The risk of bias and the quality of evidence was assessed using the quality in prognostic studies tool (QUIPS).<\/jats:p>\n                  <jats:p>\n                    A total of 10 prognostic factors were identified and evaluated in patients with CLL on anti-CD20 antibody-containing CIT. The predictive value of the following prognostic factors was confirmed and associated with poor patient outcomes; deletion 17p (HR\u2009=\u20093.39), Immunoglobulin heavy chain variable region gene mutation status (HR\u2009=\u20090.96) and \u03b2\n                    <jats:sub>2-<\/jats:sub>\n                    microglobulin (HR\u2009=\u20091.41).\n                  <\/jats:p>\n                  <jats:p>Conventional predictive factors may have retained prognostic value and could be useful in the stratification of patients who may be non-responsive to CIT.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    International Prospective Register of Systematic Reviews (PROSPERO) registry (CRD42021218997).\n                  <\/jats:p>","DOI":"10.1186\/s12885-022-10223-0","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:31:19Z","timestamp":1669393879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors"],"prefix":"10.1186","volume":"22","author":[{"given":"Zekhethelo A.","family":"Mkhwanazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda M.","family":"Nyambuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snenhlanhla A.","family":"Mfusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani B.","family":"Nkambule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"10223_CR1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1586\/era.10.127","volume":"10","author":"JG Gribben","year":"2010","unstructured":"Gribben JG. Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther. 2010;10:1389\u201394.","journal-title":"Expert Rev Anticancer Ther"},{"key":"10223_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"10223_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3324\/haematol.2013.101378","volume":"99","author":"D Catovsky","year":"2014","unstructured":"Catovsky D, Wade R, Else M. The clinical significance of patients\u2019 sex in chronic lymphocytic leukemia. Haematologica. 2014;99:1088\u201394.","journal-title":"Haematologica"},{"key":"10223_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/10428190400029965","volume":"46","author":"S Molica","year":"2005","unstructured":"Molica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, et al. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2005;46:553\u201360.","journal-title":"Leuk Lymphoma"},{"key":"10223_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Bj\u00f6rkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973\u20132003 in Sweden. Haematologica. 2009;94:1259\u201365.","journal-title":"Haematologica"},{"key":"10223_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12040894","volume":"12","author":"JA Cohen","year":"2020","unstructured":"Cohen JA, Bomben R, Pozzo F, Tissino E, H\u00e4rzschel A, Hartmann TN, et al. An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic leukemia in the context of chemoimmunotherapy and novel targeted therapy. Cancers. 2020;12:1\u201317.","journal-title":"Cancers"},{"key":"10223_CR7","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2013.783913","volume":"54","author":"R Rosenquist","year":"2013","unstructured":"Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: Where do we stand? Leuk Lymphoma. 2013;54:2351\u201364.","journal-title":"Leuk Lymphoma"},{"key":"10223_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","volume":"124","author":"N Pflug","year":"2014","unstructured":"Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49\u201362.","journal-title":"Blood"},{"key":"10223_CR9","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","volume":"112","author":"LZ Rassenti","year":"2008","unstructured":"Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112:1923\u201330.","journal-title":"Blood"},{"key":"10223_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"6814149","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Lawrence M, et al. Mutations driving CLL and their evolution in progression and relapse HHS public access cologne cluster of excellence in cellular stress responses in aging-associated diseases. Ivana Bozic Nature. 2015;6814149:525\u201330.","journal-title":"Ivana Bozic Nature"},{"key":"10223_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/10428199609054782","volume":"22","author":"M Hallek","year":"1996","unstructured":"Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, et al. Serum \u03b22-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22:439\u201347.","journal-title":"Leuk Lymphoma"},{"key":"10223_CR12","doi-asserted-by":"crossref","unstructured":"Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology. 2017;329\u201337.","DOI":"10.1182\/asheducation-2017.1.329"},{"key":"10223_CR13","doi-asserted-by":"crossref","unstructured":"Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133:1011\u20139.","DOI":"10.1182\/blood-2018-10-879429"},{"key":"10223_CR14","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328.","journal-title":"N Engl J Med"},{"key":"10223_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310.","journal-title":"N Engl J Med"},{"key":"10223_CR16","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-C\u00e9ligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756\u201365.","journal-title":"J Clin Oncol"},{"key":"10223_CR17","doi-asserted-by":"crossref","unstructured":"Hallek M, Fischer K, Fink AM, Busch R, Mayer J, Hensel M, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. 2010;376:1164\u201374.","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"10223_CR18","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1586\/era.11.132","volume":"11","author":"S Jaglowski","year":"2011","unstructured":"Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011;11:1379\u201390.","journal-title":"Expert Rev Anticancer Ther"},{"key":"10223_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractor y acute lymphoblastic leukemia. Haematologica. 2016;101:1524\u201333.","journal-title":"Haematologica"},{"key":"10223_CR20","first-page":"1356","volume":"59","author":"LJ Lee","year":"2018","unstructured":"Lee LJ, Toze CL, Huang SJT, Gillan TL, Connors JM, Sehn LH, et al. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia\u202f: a comparative effectiveness analysis in the province of British Columbia. Canada. 2018;59:1356\u201363.","journal-title":"Canada"},{"key":"10223_CR21","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079\u201388.","journal-title":"J Clin Oncol"},{"key":"10223_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/cncr.21554","volume":"106","author":"W Wierda","year":"2006","unstructured":"Wierda W, O\u2019Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, et al. A retrospective comparison of three sequential groups of patients with recurrent\/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006;106:337\u201345.","journal-title":"Cancer"},{"key":"10223_CR23","doi-asserted-by":"crossref","unstructured":"Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: When, How Long, How Much, and in Which Combination? American Society of Clinical Oncology Educational Book. 2016;36:e387\u201398.","DOI":"10.1200\/EDBK_159018"},{"key":"10223_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1634\/theoncologist.2017-0150","volume":"23","author":"JR Brown","year":"2018","unstructured":"Brown JR, Cymbalista F, Sharman J, Jacobs I, Nava-Parada P, Mato A. The role of rituximab in chronic lymphocytic leukemia treatment and the potential utility of biosimilars. Oncologist. 2018;23:288\u201396.","journal-title":"Oncologist"},{"key":"10223_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219\u201334.","journal-title":"Blood"},{"key":"10223_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198\u2013206.","journal-title":"Cancer"},{"key":"10223_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International T","year":"2016","unstructured":"International T. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390.","journal-title":"Lancet Oncol"},{"key":"10223_CR28","doi-asserted-by":"publisher","unstructured":"Kreuzberger N, Jaag D, Trivella M, Lj E, Aldin A, Umlau L, et al. Kreuzberger N, Damen JAAG, Trivella M, Estcourt LJ, Aldin A, Umlau L, Vazquez-Montes MDLA, Wol R, Moons KGM, Monsef I, Foroutan F, Kreuzer KA, Skoetz N. 2020. https:\/\/doi.org\/10.1002\/14651858.CD012022.pub2.www.cochranelibrary.com.","DOI":"10.1002\/14651858.CD012022.pub2.www.cochranelibrary.com"},{"key":"10223_CR29","doi-asserted-by":"crossref","unstructured":"Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018;8:1\u201310.","DOI":"10.1038\/s41408-018-0131-2"},{"key":"10223_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00222-3","volume":"8","author":"X Yun","year":"2020","unstructured":"Yun X, Zhang Y, Wang X. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomarker Res. 2020;8:1\u201311.","journal-title":"Biomarker Res"},{"key":"10223_CR31","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200603210-00010","volume-title":"Evaluation of the quality of prognosis studies in systematic reviews","author":"JA Hayden","year":"2006","unstructured":"Hayden JA, C\u00f4 P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. 2006."},{"key":"10223_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2014-05-575407","volume":"124","author":"CS Tam","year":"2014","unstructured":"Tam CS, Seymour JF. A new prognostic score for CLL. Blood. 2014;124:1\u20132.","journal-title":"Blood"},{"key":"10223_CR33","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1080\/10428190412331272703","volume":"45","author":"I Munk Pedersen","year":"2004","unstructured":"Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma. 2004;45:2365\u201372.","journal-title":"Leuk Lymphoma"},{"key":"10223_CR34","doi-asserted-by":"crossref","unstructured":"Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS Checklist. PLoS Med. 2014;11:1\u201312.","DOI":"10.1371\/journal.pmed.1001744"},{"key":"10223_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374.","journal-title":"Biometrics"},{"key":"10223_CR36","doi-asserted-by":"crossref","unstructured":"Schroll JB, Moustgaard R, G\u00f8tzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011;11:1\u20138.","DOI":"10.1186\/1471-2288-11-22"},{"key":"10223_CR37","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:1\u20139.","DOI":"10.1136\/bmj.d5928"},{"key":"10223_CR38","doi-asserted-by":"crossref","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101\u201329.","DOI":"10.2307\/3001666"},{"key":"10223_CR39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343.","journal-title":"N Engl J Med"},{"key":"10223_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"10223_CR41","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849\u201361.","journal-title":"J Clin Oncol"},{"key":"10223_CR42","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","volume":"58","author":"T Robak","year":"2017","unstructured":"Robak T, Warzocha K, GovindBabu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58:1084\u201393.","journal-title":"Leuk Lymphoma"},{"key":"10223_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/ejh.13042","volume":"100","author":"T Robak","year":"2018","unstructured":"Robak T, B\u0142o\u0144ski J, Skotnicki AB, Piotrowska M, Wr\u00f3bel T, Rybka J, et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. Eur J Haematol. 2018;100:465\u201374.","journal-title":"Eur J Haematol"},{"key":"10223_CR44","doi-asserted-by":"publisher","unstructured":"Greil R, Obrtl\u00edkov\u00e1 P, Smolej L, Koz\u00e1k T, Steurer M, Andel J, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to fi rst-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. 2016. https:\/\/doi.org\/10.1016\/S2352-3026(16)30045-X.","DOI":"10.1016\/S2352-3026(16)30045-X"},{"key":"10223_CR45","doi-asserted-by":"crossref","unstructured":"Dartigeas C, Neste E Van Den, L\u00e9ger J, Maisonneuve H, Berthou C, Dilhuydy M, et al. Articles Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. 2017;3026.","DOI":"10.1016\/S2352-3026(17)30235-1"},{"key":"10223_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200\u201311.","journal-title":"Lancet Oncol"},{"key":"10223_CR47","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873\u201383.","journal-title":"Lancet"},{"key":"10223_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43\u201356.","journal-title":"Lancet Oncol"},{"key":"10223_CR49","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"10223_CR50","doi-asserted-by":"crossref","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Ian W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391.","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"10223_CR51","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","volume":"16","author":"MHJ van Oers","year":"2015","unstructured":"van Oers MHJ, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): An open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16:1370\u20139.","journal-title":"Lancet Oncol"},{"key":"10223_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1365-2141.2009.07699.x","volume":"145","author":"J Delgado","year":"2009","unstructured":"Delgado J, Pratt G, Phillips N, Briones J, Fegan C, Nomdedeu J, et al. Beta 2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol. 2009;145:801\u20135.","journal-title":"Br J Haematol"},{"key":"10223_CR53","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S2352-3026(17)30235-1","volume":"5","author":"C Dartigeas","year":"2018","unstructured":"Dartigeas C, Van Den Neste E, L\u00e9ger J, Maisonneuve H, Berthou C, Dilhuydy MS, et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018;5:e82\u201394.","journal-title":"Lancet Haematol"},{"key":"10223_CR54","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1200\/JCO.2006.09.4508","volume":"25","author":"AM Tsimberidou","year":"2007","unstructured":"Tsimberidou AM, Wen S, O\u2019Brien S, McLaughlin P, Wierda WG, Ferrajoli A, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol. 2007;25:4648\u201356.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10223-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T19:29:22Z","timestamp":1669404562000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10223-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10223"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10223-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"30 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable The current study reports on publicly available data and no participant-level data were obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial or academic interests that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1218"}}